Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 06:46:08 14/05/2024 BST			5-day change	1st Jan Change
0.65 ^AUD	-2.26%		+4.84%	+27.45%

04-16	Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy	MT
04-12	Argenica Therapeutics Raises AU$12 Million via Placement	MT

Argenica Therapeutics with Proactive at the ASX Small and Mid-Cap Conference

March 22, 2023 at 04:51 pm

(via NewsDirect)

Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Its lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Argenica Therapeutics Limited

Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy	04-16	MT
Argenica Therapeutics Raises AU$12 Million via Placement	04-12	MT
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial	04-10	MT
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%	03-28	MT
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%	03-25	MT
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%	02-12	MT
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024	12-14	MT
Argenica Therapeutics Appoints Nonexecutive Chair	11-30	MT
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023	11-29	CI
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication	11-15	MT
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023	11-13	MT
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023	27/10/23	CI
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model	18/10/23	MT
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial	12/09/23	MT
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	22/08/23	CI
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders	02/08/23	MT
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial	19/07/23	MT
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial	23/06/23	MT
22,625,752 Ordinary Shares of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 11-JUN-2023.	10/06/23	CI
8,300,000 Options of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 9-JUN-2023.	08/06/23	CI
Argenica Therapeutics Raises AU$4 Million for Phase Two Trial	02/06/23	MT
Argenica Therapeutics Confirms Effectivity of Neuroprotective Medication in Preclinical Study; Shares Fall 5%	20/04/23	MT
Argenica Therapeutics Validates Safety Profile of Neuroprotective Drug	06/03/23	MT
Argenica Therapeutics Limited Releases Safety Data for its Phase 1 Clinical Trial of ARG-007 in Healthy Human Volunteers	05/03/23	CI

Chart Argenica Therapeutics Limited

Duration

Period

More charts

Company Profile

Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARGENICA THERAPEUTICS LIMITED	+27.45%	53.96M
MODERNA, INC.	+30.34%	48.16B
IQVIA HOLDINGS INC.	-0.12%	41.73B
LONZA GROUP AG	+43.12%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.88%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.11%	18.96B
BIO-TECHNE CORPORATION	+8.86%	12.92B
MEDPACE HOLDINGS, INC.	+28.21%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.79%	11.77B

Other Biotechnology & Medical Research